J&J(JNJ)
Search documents
I was laid off from CrowdStrike and used AI to send 800 applications in a month to land my ideal role
Business Insider· 2026-01-24 11:10
Core Insights - The job market is experiencing significant challenges, particularly for those laid off due to automation and AI-driven changes in companies [2][12] - AI is being utilized in the job application process, both as a tool for job seekers and as a screening mechanism by employers, leading to a complex and often frustrating experience [12][13] Company Impact - Companies are increasingly automating workflows, resulting in layoffs and pushing employees back into a competitive job market [12] - The reliance on AI for screening applicants creates a barrier for job seekers, as they must navigate opaque criteria that may not favor them [12][13] Job Seeker Experience - The job search process has become tedious and draining, with many applicants feeling lost in the system, particularly when using platforms like LinkedIn [6][7] - AI-powered application platforms can assist job seekers by automating the application process, allowing them to focus on interview preparation and networking [9][10] - Despite the challenges, AI can provide significant advantages when used effectively, helping job seekers regain momentum in their job search [14]
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
ZACKS· 2026-01-23 18:55
Key Takeaways JNJ topped Q4 EPS and sales estimates, driven by strong growth in Innovative Medicines and MedTech segments.Johnson & Johnson expects higher 2026 cash flow on R&D, M&A investments, and multiple new drug launches.IHE offers diversified exposure to JNJ after its earnings surprise and brief post-report dip.Medtech giant Johnson & Johnson (JNJ) announced better-than-expected fourth-quarter 2025 results on Jan. 21, 2026. The company continued its streak of earnings beats and also beat on sales est ...
Goldman Sachs Says Correction Could Be Coming: 5 Safe Dividend Stocks From the Conviction List
247Wallst· 2026-01-23 14:11
Company Overview - Goldman Sachs, founded in 1869, is the world's second-largest investment bank by revenue and ranks 55th on the Fortune 500 list of largest U.S. corporations by total revenue [1] - The firm offers a range of services including financing, advisory services, risk distribution, and hedging for institutional and corporate clients, maintaining its leadership in the investment landscape [1] Market Insights - Timothy Moe, Chief Head of APAC Equity Strategy at Goldman Sachs, highlighted a historical pattern of market corrections occurring every eight to nine months, indicating that the market is overdue for a correction [2] - The firm is increasingly focusing on the energy sector, predicting that while prices may remain flat or decline this year, they could rise starting in 2027 [2] Investment Recommendations - Goldman Sachs has identified five top stocks for investors to consider, particularly emphasizing two companies in the energy sector that are expected to perform well in the future [3] - The firm maintains its status as a premier financial institution, being the go-to bank for a wide range of financial needs over the past 15 years [4] Stock Highlights - **Brixmor Property Group**: This REIT offers a 4.31% dividend and has a target price of $32, indicating a 23% upside potential [5][7] - **Duke Energy**: An electric power and natural gas holding company with a 3.52% dividend and a target price of $141, representing a 20% gain from current levels [8][9] - **Hershey**: A snacks company with a 2.77% dividend and a target price of $220, suggesting a 21% potential increase [10][13] - **Johnson & Johnson**: A diversified healthcare company with a 2.31% dividend and a target price of $240, indicating a 16% upside [14][16] - **Valero Energy**: A multinational manufacturer of petroleum products with a 2.43% dividend and a target price of $197, representing a 19% gain [17][20]
Is This Dividend King a Screaming Buy?
The Motley Fool· 2026-01-23 09:44
Maybe there won't be any screaming about this stock. But there could be some buying.Johnson & Johnson (JNJ +0.22%) has been in business since 1886. The company has experienced significant success along the way. However, its share price has never been higher than the levels already achieved in the first few weeks of 2026. CEO Joaquin Duato said in J&J's fourth-quarter update earlier this week that 2025 "kicked off a new era of accelerated growth" for the company. Is the healthcare stock a screaming buy now? ...
花旗上调强生目标价至250美元
Ge Long Hui A P P· 2026-01-23 08:55
格隆汇1月23日|花旗将强生的目标价从232美元上调至250美元,维持"买入"评级。(格隆汇) ...
百万抗癌药海外大卖,传奇生物要扭亏了?
Jin Rong Jie· 2026-01-23 05:45
美国当地时间1月21日,强生(JNJ.US)公布2025年全年财报,公司全年营收为941.93亿美元,同比增 长6%。创新药中肿瘤治疗领域对强生的贡献最大,其中最引人瞩目的当属其与传奇生物(LEGN.US) 共同开发并商业化的西达基奥仑赛。 财报显示,西达基奥仑赛在2025年第四季度销售额达5.55亿美元,同比增长65.8%,但环比增速有所放 缓,仅5.9%。2025年第三季度,这一产品实现了净销售额5.24亿美元,环比增长19.4%;而在2024年第 四季度,该产品销售额则环比增长16.7%。 全年来看,2025年,西达基奥仑赛贡献收入为18.87亿美元,与2024年同期收入9.63亿美元相比,增长 95.95%。 18.87亿美元,意味着,西达基奥仑赛已成为国产"十亿美元分子",但距离市场预期中的20亿美元年销 售额还差一步之遥。或受此消息影响,财报披露后,传奇生物盘中一度跌超15%,当日美股收盘时报收 20.76美元/股,跌11.36%,总市值为38.34亿美元。 就西达基奥仑赛在中国市场的定位,以及对商保创新药目录的看法,传奇生物方面告诉时代财经,暂时 无法回答。 明星抗癌药CAR-T细胞疗法西达基奥 ...
收入942亿美元!强生公布2025财报
思宇MedTech· 2026-01-23 04:38
2026 年 1 月 21 日,强生 Johnson & Johnson 发布 2025 年第四季度及全年业绩。 整体来看,这是一份"稳健增长"的财报。增长不再依赖一次性事件,而是重新回到创新药与医疗技术双轮驱动的基本面。 一、整体业绩:规模型企业中的"可持续增长" 2025 年全年,强生实现营收 942 亿美元 ,同比增长 6.0% ;按运营口径(剔除汇率影响)计算,增长 5.3% 。 全年摊薄后每股收益(EPS)为 11.03 美元 ,调整后 EPS 为 10.79 美元 。 单看第四季度,增长节奏有所加快: 值得注意的是,财报中多项利润指标仍包含因 Halda Therapeutics 收购 带来的约 0.10 美元/股 影响,在此基础上仍实现双位数利润增长,反映出经营层面的弹 性。 | | | 04 | | Full Year | | | | --- | --- | --- | --- | --- | --- | --- | | ($ in Millions, except EPS) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | | Repor ...
远超行业平均增速,增长最快的十大医疗器械爆品
3 6 Ke· 2026-01-23 01:40
脉冲电场消融(PFA) 心脏电生理脉冲电场消融增长一骑绝尘。PFA作为创新产品,获批后仅用了不到两年的时间,在美国电生理市场实现了渗透率超过20%,市场规模冲破20 亿美元。投资人认为其有望成为国内外有史以来收入增速和市场规模起量最快的一个赛道。 图片来源:波士顿科学 PFA能够快速提升渗透率,首先在于其突出的临床价值。脉冲电场消融和射频消融、冷冻消融不同,其组织选择性高,能够在有效消融病变心肌细胞的同 时,最大程度避免对邻近食道、膈神经、冠状动脉等重要结构的损伤。初步消融效果明确,研究显示其肺静脉隔离即刻成功率达98% - 100%。多项研究 1 年随访结果提示其对于阵发性房颤单次手术成功率为 70% - 80%,不劣于传统温度消融,且在部分研究中表现出更好的长期效果。还能缩短手术时间,提 升手术效率。 在商业化上,巨头齐齐布局和大力推动助推PFA快速渗透。波士顿科学、美敦力是当下全球PFA市场主导者,两家心血管领域巨头投入大量资源推动PFA 商业化。波士顿科学的Farapulse PFA系统全球手术量已突破50万例。2025财年,美敦力PFA消融收入约10亿美元,预计2026年收入还将再增加10亿美元。 ...
8点1氪丨错版“马年茅台”二手价格被炒至2800元 ;“黑白颠周媛”账号被封;兰博基尼2025销量创历史新高,卖出10747辆
3 6 Ke· 2026-01-23 00:03
"马年茅台"出现印刷错误,错版二手价格被炒至2800元 1月21日,53%vol500ml贵州茅台酒(丙午马年)经典版印刷错误的消息引发关注。有网友指出,马年 茅台外包装所印制的星宿图中,"昴宿"的"昴"字被错印成了形近字"昂"。目前,茅台已确认并修改,有 白酒专家称错版马茅因稀缺性或有升值空间。 1月22日,记者搜索发现,二手平台已有多个卖家出售2026年"错版马茅"。原价1899元一瓶的"错版马 茅"二手标价在2300元至2800元不等。还有加价500元卖2499元一瓶的商家称,已经接到茅台专卖店的召 回电话。"包装印刷错了很特别,很难抢。"另有以14998元出售6瓶整箱马茅、生产日期在20260116吉利 顺顺号的卖家称,错版茅台更有收藏价值。(江南都市报) 今日热点导览 TOP 3 大新闻 "黑白颠周媛"账号被封,此前付费课程收入已超过2400万元 近日"眼神给出去,我的身体形成X形"成为互联网热梗,网红周媛因为教女性向男性撒娇的片段引发争 议,骂声也随之而来。网友指责她发布擦边低俗视频。记者1月22日获悉,"黑白颠周媛"实名主账号已 被封。 然而在玩梗与热闹之外,周媛背后还隐藏着一个覆盖知识付费、情 ...
These 4 turnarounds are making headway – plus, updates on our 30 other stocks
CNBC· 2026-01-22 20:33
Jim Cramer and Jeff Marks, the Club's director of portfolio analysis, on Thursday delivered updates on all 34 Club holdings during the January Monthly Meeting. Here are the highlights from the first meeting of 2026, starting with our four turnaround stories: 4 turnaround plays Nike: The apparel and sneaker retailer has shown real signs of improvement under CEO Elliott Hill, who has already stabilized Nike's U.S. market. China, another crucial segment, is up next. Procter & Gamble: The weak quarterly earning ...